|Day's Range||113.99 - 115.46|
|52 Week Range||81.12 - 121.75|
|PE Ratio (TTM)||37.98|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.
Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.
On May 25 2017, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).